George Emile

Caen, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 36 publications

Erratum: VIKTORIA-1 Trial of Gedatolisib Plus Fulvestrant With or Without Palbociclib in Hormone Receptor-Positive/HER2-/PIK3CA Wild-Type Advanced Breast Cancer.

Erratum: VIKTORIA-1 Trial of Gedatolisib Plus Fulvestrant With or Without Palbociclib in Hormone Receptor-Positive/HER2-/PIK3CA Wild-Type Advanced Breast Cancer.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: June 04, 2026

VIKTORIA-1 Trial of Gedatolisib Plus Fulvestrant With or Without Palbociclib in Hormone Receptor-Positive/HER2-/PIK3CA Wild-Type Advanced Breast Cancer.

VIKTORIA-1 Trial of Gedatolisib Plus Fulvestrant With or Without Palbociclib in Hormone Receptor-Positive/HER2-/PIK3CA Wild-Type Advanced Breast Cancer.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: March 09, 2026

Digital image analysis improves diagnostic accuracy of HER2-low and HER2-ultralow breast cancer: a step towards personalised medicine.

Digital image analysis improves diagnostic accuracy of HER2-low and HER2-ultralow breast cancer: a step towards personalised medicine.

Journal: Virchows Archiv : an international journal of pathology

Published: August 31, 2025

PROMENADE: pembrolizumab for early ER-low/HER2-negative breast cancer, real-world French cohort.

PROMENADE: pembrolizumab for early ER-low/HER2-negative breast cancer, real-world French cohort.

Journal: ESMO open

Published: July 08, 2025

Tremelimumab plus durvalumab combined to metronomic oral vinorelbine: Results from the breast cancer cohort of the phase II MOVIE study.

Tremelimumab plus durvalumab combined to metronomic oral vinorelbine: Results from the breast cancer cohort of the phase II MOVIE study.

Journal: Breast (Edinburgh, Scotland)

Published: April 29, 2025

Links between nocturnal hypoxia and cognitive function in breast cancer.

Links between nocturnal hypoxia and cognitive function in breast cancer.

Journal: Scientific reports

Published: February 12, 2025

Sleep oscillations related to memory consolidation during aromatases inhibitors for breast cancer.

Sleep oscillations related to memory consolidation during aromatases inhibitors for breast cancer.

Journal: Sleep medicine

Published: May 21, 2024

Potential of PSMA for breast cancer in nuclear medicine: digital quantitative immunohistochemical analysis and implications for a theranostic approach.

Potential of PSMA for breast cancer in nuclear medicine: digital quantitative immunohistochemical analysis and implications for a theranostic approach.

Journal: BMC cancer

Published: March 04, 2024

Overall Survival With Circulating Tumor Cell Count-Driven Choice of Therapy in Advanced Breast Cancer: A Randomized Trial.

Overall Survival With Circulating Tumor Cell Count-Driven Choice of Therapy in Advanced Breast Cancer: A Randomized Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: November 06, 2023

First-line real-world treatment patterns and survival outcomes in women younger or older than 40 years with metastatic breast cancer in the real-life multicenter French ESME cohort.

First-line real-world treatment patterns and survival outcomes in women younger or older than 40 years with metastatic breast cancer in the real-life multicenter French ESME cohort.

Journal: European journal of cancer (Oxford, England : 1990)

Published: October 10, 2023

Baseline and early 18F-FDG PET/CT evaluations as predictors of progression-free survival in metastatic breast cancer patients treated with targeted anti-CDK therapy.

Baseline and early 18F-FDG PET/CT evaluations as predictors of progression-free survival in metastatic breast cancer patients treated with targeted anti-CDK therapy.

Journal: Cancer imaging : the official publication of the International Cancer Imaging Society

Published: September 28, 2023

The TRIPLEX study: use of patient-derived tumor organoids as an innovative tool for precision medicine in triple-negative breast cancer.

The TRIPLEX study: use of patient-derived tumor organoids as an innovative tool for precision medicine in triple-negative breast cancer.

Journal: BMC cancer

Published: July 17, 2023

Showing 1-12 of 36

Last Updated: 09/26/2026